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Intranasal lysine-aspirin administration decreases polyp
volume in patients with aspirin-intolerant asthma
N OGATA*†, Y DARBY*, G SCADDING*
Abstract
Introduction: Nasal polyposis associated with aspirin-intolerant asthma tends to be difficult to control,
with frequent recurrences. We examined the effect of intranasal lysine-aspirin administration on
resistant nasal polyps of asthmatic, aspirin-intolerant patients, when used in addition to routine
therapy.
Patients and methods: Thirteen patients with asthma and intolerance to aspirin were recruited. All
but one had undergone numerous polypectomies and were uncontrolled on standard therapy with
intranasal corticosteroids, leukotriene receptor antagonists and nasal douching. Aspirin treatment
involved one drop (100 ml) of 30 mg/ml lysine-aspirin solution to each nostril, initially daily,
increased every two or three days up to a maximal of 18 drops (54 mg lysine-aspirin) a day.
Nasal symptoms, nitric oxide level, nasal inspiratory peak flow rate, peak expiratory flow rate and
nasendoscopic grading were assessed prior to therapy and three months later. We also compared
the change in endoscopic polyp scores during three months of lysine-aspirin administration with
the changes which had occurred during the three months prior to administration (during which
time other therapies had been identical).
Results: Nasal blockage symptoms tended to decrease; other nasal symptoms were unchanged.
Significant changes were seen in nasal inspiratory peak flow rate (103.3+ 18.9 and 140.0+ 16.7 l/
min before and after aspirin, respectively; p ¼ 0.014), but not in peak expiratory flow rate
(438.7+33.4 and 440.0+ 28.4 l/min before and after aspirin, respectively; p ¼ 0.700). Nasal nitric
oxide levels rose significantly (in both sides, p ¼ 0.028). Expired chest nitric oxide levels did not
change. Nasal polyp scores on nasendoscopic examination were significantly reduced (right side,
p ¼ 0.027; left side, p ¼ 0.018). Compared with the preceding three months, adding intranasal
lysine-aspirin application had the effect on decreasing nasal polyp volume (right side, p ¼ 0.031;
left side, p ¼ 0.016).
Conclusion: This open study suggests that intranasal lysine-aspirin administration reduces nasal
polyp volume in aspirin-intolerant patients, without any adverse affect on concomitant asthma.
This was a preliminary study and should be followed by a placebo-controlled, double-blind trial.
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Introduction
Nasal polyposis is frequently associated with asthma
and aspirin intolerance.1 Although intensive treat-
ment is usually undertaken in these patients, includ-
ing topical and/or systemic steroids and endoscopic
surgery, the recurrence rate is high. Polyps in these
patients are more troublesome, compared with
those in aspirin-tolerant patients.2,3
The underlying mechanisms of aspirin-intolerance
appear to be related to inhibition of cyclo-oxygenase
with subsequent release of leukotrienes and other
mediators.4 Our previous study, using the leukotriene
D4 receptor antagonist montelukast, confirmed the
evidence that leukotrienes play an important role in
the development of nasal polyps in patients with
aspirin-intolerant asthma.5
Trials of desensitisation, using aspirin, have
been reported in patients with aspirin-intolerant
asthma. Initially, the effect on asthma of oral
desensitisation was examined.6 Research then pro-
ceeded to investigate the nasal polyps of patients
with aspirin-intolerant asthma, demonstrating an
improvement in the clinical course.7,8 Recently,
attention has focussed on intranasal administration
of lysine-aspirin, the only soluble form of aspirin.
Sousa et al. demonstrated that lysine-aspirin
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reduces the numbers of cysteinyl leukotriene recep-
tors which are up-regulated in aspirin-intolerant
polyps.9 In that study, lysine-aspirin was used as
monotherapy and there was no evidence of clinical
benefit.10
In this study, we examined the effect of intranasal
lysine-aspirin administration on polyps in patients
with aspirin-intolerant asthma, when used in addition
to their routine therapy.
Materials and methods
Thirteen patients ( five men and eight women; mean
age+ standard deviation (SD) 44.5+9.3 years) with
asthma and intolerance to aspirin were recruited
from the patients of the rhinology clinics of the
Royal National Throat, Nose and Ear Hospital. All
the patients were refractory to medical therapy with
topical and/or systemic steroids, leukotriene recep-
tor antagonists and nasal douching. In addition, all
were receiving asthma therapy with inhaled corticos-
teroids and long-acting b agonists. All but one
patient had undergone endoscopic polypectomy;
patients’ mean number of operations+SD was
5.9+7.0. Aspirin sensitivity was deduced from
patients’ histories and confirmed by lysine-aspirin
nasal provocation, as previously described.5 All
patients also underwent skin prick tests with 10
common, inhaled allergens. Seven patients had posi-
tive reactions to house dust mite, pollen, grass, tree or
cat antigens.
Aspirin (acetylsalicylic acid) treatment was as
follows. Initially, one drop (100 ml) of 30 mg/ml
lysine-aspirin solution per nostril was administered
in the laboratory. Patients were then sent home
with sachets and instructions to make up the
lysine-aspirin freshly each day and to gradually
increase the number of drops each side every two
to three days, to a maximum of nine drops, i.e. a
maximal dose of 18 drops a day, equivalent to
54 mg of lysine-aspirin. Patients continued to take
their usual intranasal steroids and/or leukotriene
receptor antagonist during aspirin administration.
The following parameters were assessed before
intranasal lysine-aspirin administration: nasal symp-
toms (via symptom questionnaires), nitric oxide
level, nasal inspiratory peak flow rate, peak expiratory
flow rate and nasendoscopic grading. After at least
three months, these parameters were reassessed and
compared with the earlier results. Twelve of the 13
patients underwent final assessment. One patient
ceased treatment because of nasal pain.
Changes in patients’ nasal polyp scores following
lysine-aspirin administration were also compared
with those during the three months prior to adminis-
tration, during which time therapy, other than
lysine-aspirin, had been identical.
Symptom score
A visual analogue scale of 0 to 10 cm was used to
assess sneezing, itchiness, nasal blockage and nasal
discharge.
Nasal inspiratory peak flow
Nasal inspiratory peak flow was assessed as pre-
viously described,11 in triplicate, using a nasal
inspiratory peak flow meter, with the best of three
values being recorded.
Peak expiratory flow
Peak expiratory flow was also assessed in triplicate,
with the best of three values being recorded.
Nitric oxide
Nitric oxide levels were assessed by chemilumines-
cence, using the Logan–Sinclair analyser (Logan
Research, Rochester, UK). Recordings were made
from both sides of the nose and from the lower respir-
atory tract, according to European guidelines.12
Nasendoscopy
The Lund and Mackay endoscopic scoring system
was applied, with minor variations.13 Polyps were
classified into seven grades: 0.0, 0.5, 1.0, 1.5, 2.0, 2.5
and 3.0. Polyps in the right and left nasal cavities
were evaluated and compared separately.
Statistical analysis
A one-tailed Wilcoxon matched pairs signed rank
test was used to analyse data within the groups.
P values below 0.05 were regarded as significant.
Applicable data were expressed as mean+ standard
error of the mean.
Results and analysis
Symptoms
Initial administration of 100 ml lysine-aspirin caused
a small increase in nasal symptoms, especially block-
age, commencing at one hour and lasting for several
hours. Subsequent daily administration was followed
by an increase in nasal symptoms for up to three
weeks; thereafter, no symptomatic reaction occurred.
There was no deterioration in asthma symptoms or
control. One patient experienced nasal pain follow-
ing each lysine-aspirin administration and stopped
the treatment after two weeks.
At three months, there was a tendency towards
improvement of nasal blockage (nasal blockage
symptom scores were 8.45+0.53 before and 6.94+
0.79 after regular lysine-aspirin administration; p ¼
0.09). Other symptoms were not improved by intra-
nasal lysine-aspirin administration.
Objective measurements
Significant improvements were seen in nasal inspira-
tory peak flow rate (103.3+18.9 l/min before and
140.0+ 16.7 l/min after intervention; p ¼ 0.014),
but not in peak expiratory flow rate (438.7+33.4
l/min before and 440.0+28.4 l/min after interven-
tion; p ¼ 0.700) (Figure 1).
Patients initially had low nasal nitric oxide levels,
but these rose significantly following aspirin adminis-
tration ( for right side, 234+ 86.1 ppb before and
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464.0+ 144.6 ppb after intervention; for left side,
226.7+ 80.1 ppb before and 533.0+158.8 ppb after
intervention; for both sides, p ¼ 0.028). Chest nitric
oxide levels did not change (20.34+ 6.85 ppb
before and 18.93+4.53 ppb after intervention;
p ¼ 0.735) (Table I).
Nasendoscopic examination showed that nasal
polyp grading scores on both sides were significantly
reduced following lysine-aspirin administration (on
right side, 1.9+0.2 before and 1.0+0.3 after inter-
vention; p ¼ 0.027; on left side, 1.9+ 0.2 before and
1.2+ 0.3 after intervention; p ¼ 0.018) (Table I).
We also compared the change in endoscopic polyp
grading scores after three months of lysine-aspirin
administration with the changes which had occurred
during the previous three months (Figure 2).These
demonstrated a significant improvement on both
sides of the nose (on right, p ¼ 0.031; on left, p ¼
0.016) during the lysine-aspirin treatment period,
compared with the previous period, during which
all other treatment had remained identical.
Discussion
Samter’s triad consists of nasal polyps, asthma and
aspirin intolerance.1 The inhibition of
cyclo-oxygenases I and II by aspirin results in the
diversion of arachidonic acid products toward the
lipoxygenase pathway, resulting in overproduction of
leukotrienes and other mediators, and a reduction of
anti-inflammatory prostaglandin E2. This is thought
to cause an exacerbation of asthma and the formation
of nasal polyps.4
Intranasal therapy with lysine-aspirin has been
reported to be effective in both aspirin-sensitive
and aspirin-tolerant nasal polyps.9,14 – 16 Nucera
et al.15 showed, in an open study, that the relapse
rates of nasal polyps after medical or surgical poly-
pectomy were significantly lower than those for a
non-randomised control group, in patients receiving
a low (sub-desensitising) dose of lysine-aspirin once
weekly. Although we previously attempted to ascer-
tain the effects of desensitising doses of intranasal
lysine-aspirin in aspirin-sensitive polyps, there was
no evidence of clinical benefit when lysine-aspirin
was used alone.10
In this open study, we examined the effect of
lysine-aspirin administration in doses sufficient for
local desensitisation, in addition to routine therapy.
Our findings showed that lysine-aspirin desensitisation
reduces on-going polyps. Lysine-aspirin tended to
decrease nasal blockage symptoms, and this was con-
firmed by significant objective findings for nasal
inspiratory peak flow rates, nasal nitric oxide levels
and nasendoscopy scores. Significant improvement
was found in nasal inspiratory peak flow rates,
which supports the reported decrease in nasal block-
age symptoms. Nasendoscopic examination showed
that nasal polyps were significantly reduced by
lysine-aspirin administration. In our study,
lysine-aspirin administration also significantly elev-
ated nitric oxide levels in the nose; this has previously
FIG. 1
(a) Nasal inspiratory peak flow (NIPF) and (b) peak expiratory
flow rate (PEFR) before and after lysine-aspirin
administration in asthmatic patients with aspirin-intolerant
nasal polyps. There was a significant difference in NIPF but
not in PEFR. Horizontal lines indicate mean values.
TABLE I
NASAL NITRIC OXIDE LEVEL AND POLYP SCORE BEFORE AND AFTER
LYSINE-ASPIRIN ADMINISTRATION
Parameter Before LAA After LAA p
Nitric oxide (ppb)
Nasal
2 R 234.9 (86.1) 464.0 (144.6) 0.028
2 L 226.7 (80.1) 533.0 (158.8) 0.028
Chest 20.34 (6.85) 18.93 (4.53) 0.735
Nasal polyp (score)†
R 1.9 (0.2) 1.0 (0.3) 0.027
L 1.9 (0.2) 1.2 (0.3) 0.018
n¼7; †n ¼ 10. Data are shown as mean (standard error of the
mean). LAA ¼ lysine-aspirin administration; R ¼ right;
L ¼ left
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been shown to be associated with a reduction in polyp
volume.17 These results indicate that intranasal
lysine-aspirin administration influences polyps
directly.
Since we did not have a control group in this pre-
liminary study, we compared changes in nasal polyp
scores after lysine-aspirin administration with
changes seen in the same patients in the previous
three months. There were no differences in patients’
medical therapy between the two periods, except for
intranasal lysine-aspirin administration. Patients had
not undergone any surgical treatment during this
period. In the three months before intervention,
only one nostril demonstrated any decrease in polyp
size; all others were refractory to therapy. As a
result of adding lysine-aspirin, a reduction of nasal
polyp volume was seen in each nostril, suggesting a
beneficial effect of intranasal lysine-aspirin
administration.
There were no significant differences in other
symptoms, such as nasal secretion, itchiness and
sneezing, suggesting that lysine-aspirin does not
affect basic rhinitis mechanisms.
Although the precise mechanism of aspirin desen-
sitisation is still unclear, our previous study showed
that the cysteinyl leukotriene receptors were down-
regulated, which may be fundamental.9 Others have
pointed out a decline in the peripheral monocyte syn-
thesis of leukotriene B4 after aspirin desensitisa-
tion.18 On the other hand, there is also evidence
that the anti-proliferative effect of aspirin is the
major mechanism, with aspirin having a non-specific,
dose-dependent inhibitory effect on fibroblast
proliferation.19
. Nasal polyposis associated with
aspirin-intolerant asthma tends to be difficult
to control, with frequent recurrences
. This study examined the effect of intranasal
lysine-acetylsalicylate administration on
resistant polyps of aspirin-intolerant patients,
when used in addition to routine therapy
. This open study suggests that intranasal
lysine-acetylsalicylate administration reduces
polyp volume in aspirin-intolerant patients,
without any adverse affect on concomitant
asthma
. This is a preliminary study and should be
followed by a placebo-controlled,
double-blind trial
Intranasal lysine-aspirin administration did not
affect lung function, as assessed by peak expiratory
flow rate, and patients did not complain about any
exacerbation of asthma during this trial. Side effects
from gastritis, which have been reported in 20 per
cent of patients undergoing oral aspirin desensitisa-
tion, were not seen in this study.20 Only one patient
suffered from nasal pain, which improved on cessa-
tion of treatment.
This preliminary study should be followed by a
placebo-controlled, double-blind trial.
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